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Abstract
The cytochrome p450 family 19 gene (CYP19A1) encodes for aromatase, which catalyzes the final 
step in estrogen biosynthesis and conversion of androgens to estrogens. Genetic variation in 
CYP19A1 is linked to higher circulating estrogen levels and increased aromatase expression. 
Using data from the Breast Cancer Health Disparities Study, a consortium of three population-
based case–control studies in the United States (n = 3,030 non-Hispanic Whites; n = 2,893 
Hispanic/Native Americans (H/NA) and Mexico (n = 1,810), we examined influence of 25 
CYP19A1 tagging single-nucleotide polymorphisms (SNPs) on breast cancer risk and mortality, 
considering NA ancestry. Odds ratios (ORs) and 95 % confidence intervals (CIs) and hazard ratios 
estimated breast cancer risk and mortality. After multiple comparison adjustment, none of the 
SNPs were significantly associated with breast cancer risk or mortality. Two SNPs remained 
significantly associated with increased breast cancer risk in women of moderate to high NA 
ancestry (≥29 %): rs700518, ORGG 1.36, 95 % CI 1.11–1.67 and rs11856927, ORGG 1.35, 95 % 
CI 1.05–1.72. A significant interaction was observed for rs2470144 and menopausal status (padj = 
0.03); risk was increased in postmenopausal (ORAA 1.22, 95 % CI 1.05–1.14), but not 
premenopausal (ORAA 0.78, 95 % CI 0.64–0.95) women. The absence of an overall association 
with CYP19A1 and breast cancer risk is similar to previous literature. However, this analysis 
provides support that variation in CYP19A1 may influence breast cancer risk differently in women 
with moderate to high NA ancestry. Additional research is warranted to investigate the how 
variation in an estrogen-regulating gene contributes to racial/ethnic disparities in breast cancer.
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The cytochrome p450 family 19 gene (CYP19A1), located on chromosome 15, encodes for 
the enzyme aromatase, which catalyzes the final step in estrogen biosynthesis and 
metabolism converting androgens to estrogens, in the ovaries of premenopausal women and 
primarily in the adipose tissue of postmenopausal women [1, 2]. Genetic variation in the 
aromatase gene makes an attractive candidate to evaluate as a breast cancer risk factor due to 
this gene’s involvement in the regulation of endogenous estrogen and to the recognized 
association between estrogen exposure levels in blood and urine and breast cancer risk [3–
5]. During breast carcinogenesis, estrogen interacts with the cell cycle promoting cellular 
division and proliferation [6]. Estrogen may also act locally in surrounding adipose tissue to 
promote the growth of breast cancer [7]. Additionally, while clinical data are in agreement 
with an anti-invasive effect of estrogens, disruptions in the estrogen receptor-signaling 
pathway could lead to metastasis [8, 9].
Single-nucleotide polymorphisms (SNPs) in CYP19A1 have been shown to be associated 
with circulating estrogen levels; specifically rs727479 (T), rs10046 (T), and rs4646 (G), 
while rs700518 (G/A at Val80, located in exon 3) was found to be associated with increased 
aromatase expression [10–14]. Despite this relationship, epidemiological studies have shown 
mixed results for an association between SNPs in CYP19A1 and breast cancer risk [10, 11, 
13, 15–20]. Likewise, epidemiological studies to date show inconsistent associations 
between SNPs in CYP19A1 and breast cancer mortality [21–26]. Moreover, none of these 
studies have included Hispanic women; a genetically admixed population with European, 
Native American (NA), and African ancestry [27, 28]. In the USA and Mexico, Hispanic 
women with a higher proportion of European ancestry were found to have a higher risk of 
breast cancer [28, 29]. Additionally, previous findings suggest that the proportion of NA 
ancestry modifies the direction and strength of associations between reported genetic 
variants involved in hormones and breast cancer risk and mortality, and may contribute to 
the observed racial differences in breast cancer incidence and survival [28, 30]. It is 
plausible that gene–environment interactions involving hormonal pathways may also play a 
role in these differences, particularly given the observed variation by race in distributions of 
hormone receptor status, hormone-related risk factors, and genetic factors [31–36].
In this study, we conducted a comprehensive evaluation of associations between CYP19A1 
polymorphisms and breast cancer risk and breast cancer mortality using data from the Breast 
Cancer Health Disparities Study (BCHDS), a multicenter population-based case–control 
study including US non-Hispanic White (NHW), U.S. Hispanic/NA, and Mexican women. 
We considered potential interactions between CYP19A1 genetic variants and variables 
thought to influence the estrogen pathway [hormone therapy (HT) use, oral contraceptive 
(OC) use, menopausal status, estrogen receptor (ER), and progesterone receptor (PR) status]. 
Additionally, we considered possible heterogeneity of the association between CYP19A1 
genetic variants and breast cancer risk and mortality by race/ethnicity and NA ancestry.
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The BCHD study [28] is a consortium of three previously conducted population-based case–
control studies, the 4-Corners Breast Cancer Study (4-CBCS) [37], the San Francisco Bay 
Area Breast Cancer Study (SFBCS) [38, 39], and the Mexico Breast Cancer Study (MBCS) 
[40]. In-person interviews were conducted and blood or saliva samples were collected. The 
4-CBCS participants were non-Hispanic White, Hispanic, or NA, between 25 and 79 years 
of age and included histologically confirmed breast cancer cases (in situ or invasive) with a 
first primary diagnosed between 10/1999 and 05/2004, and controls selected from the target 
populations of cases living in Arizona, Colorado, New Mexico, and Utah and were 
frequency-matched to cases on ethnicity and 5-year age distribution. SFBCS participants 
were aged 35–79 years from the San Francisco Bay Area diagnosed with a first primary 
histologically confirmed invasive breast cancer between 04/1995 and 04/2002 (Hispanics) or 
between 04/1995 and 04/1999 (NHWs); and controls were identified by random-digit 
dialing and frequency-matched to cases on ethnicity and 5-year age distribution. MBCS 
participants were between 28 and 74 years of age: Cases were women diagnosed with a new 
histologically confirmed breast cancer (in situ or invasive) between 01/2004 and 12/2007 at 
12 participating hospitals from three main health care systems; controls were randomly 
selected from the catchment area of the 12 participating hospitals using a probabilistic 
multistage design. All participants signed informed written consent prior to interview, and 
all studies were approved by their corresponding Institutional Review Board for Human 
Subjects.
Data harmonization
Data were harmonized across all study centers and questionnaires as previously described 
[28]. Women were classified as either premenopausal or postmenopausal based on responses 
to questions on menstrual history and hormone therapy (HT) use. Women who reported still 
having periods during the referent year were classified as premenopausal. Study-specific 
definitions were used to define postmenopausal women. Women were classified as 
postmenopausal if: (1) they reported a natural menopause; or (2) they reported taking HT 
and were still having periods and were at or above the 95th percentile of age for race/
ethnicity of those who reported having a natural menopause (i.e., >12 months since their last 
period) within their study center. The age at which ≥95 % of women reported having a 
natural menopause was 58 for NHW and 56 for Hispanics from the 4-CBCS, 55 for NHW 
and 56 for Hispanics from the SFBCS, and 54 for the MBCS. Race/ethnicity was self-
reported for 4-CBCS and SFBCS; all women from MBCS were considered Hispanic 
ethnicity.
Genetic data
DNA was extracted from available whole-blood (n = 7,287) or saliva (n = 634) samples. 
Whole-genome amplification (WGA) was applied to the saliva-derived DNA samples prior 
to genotyping. A tagSNP approach was utilized to characterize variation across the 
candidate gene. TagSNPs were selected using the following parameters: (1) Linkage 
disequilibrium (LD) blocks were defined using a Caucasian LD map and an r2 = 0.8 [41]; 
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(2) minor allele frequency (MAF) >0.1; (3) range±1,500 base pairs from the initiation codon 
or termination codon; and (4) 1 SNP/LD bin [28]. Variants within 3 kb were included to 
capture the majority of the regulatory region of the CYP19A1 gene. This approach is similar 
to one employed by Stram et al. [42], which was based on the genotyping of a high density 
of SNPs selected every 3–5 kb in and surrounding a candidate gene. Additionally, 104 
ancestry informative markers (AIMs) were used to distinguish European and NA ancestry 
[28, 43]. All markers were genotyped using a multiplexed bead array assay format based on 
GoldenGate chemistry (Illumina, San Diego, California). A genotyping call rate of 99.93 % 
was attained (99.65 % for WGA samples). We included 132 blinded internal replicates 
representing 1.6 % of the sample set. The duplicate concordance rate was 99.996 % as 
determined by 193,297 matching genotypes among sample pairs [28]. We investigated 
associations with 25 CYP19A1 tagSNPs: rs4275794, rs4646, rs2899472, rs700518, 
rs17703883, rs727479, rs10459592, rs12591359, rs12908960, rs7172156, rs11856927, 
rs2414099, rs17601876, rs2470158, rs730154, rs17523880, rs2470152, rs3751591, 
rs1902584, rs2445762, rs2470144, rs7174997, rs8025191, rs1961177, and rs6493497. We 
attempted to capture all of the variation across the CYP19A1 gene using the 25 tagSNPs so 
that we have active surrogate markers, detecting all variants. These markers should be 
covering all of the unmeasured variants with 80 % correlation or better. These tag SNPs 
were chosen based on information obtained HapMap databases and were not supposed to be 
in high LD with one another. Supplemental Graph 1 includes an LD matrix stratified by 
ethnicity which shows that LD between SNPs is not high (r2 < 0.80) and is similar between 
ethnic groups for the most part. However, LD differs by ethnic groups for a few SNPs, for 
example: rs2899472 and rs2470158 are considered to be in high LD within NHW women 
(r2 = 0.80), but not within Hispanic/NA women (r2 = 0.52). Approximately four sets of 
SNPs (eight total SNPs) were considered to be in very high LD (r2 > 0.80) for both ethnic 
groups.
Tumor characteristics and survival data
Data on tumor characteristics and survival were not available for cases from Mexico; 
therefore, evaluation of these variables was limited to data (available through Spring 2012) 
obtained from 4-CBCS and SFBCS. Statewide cancer registries in Arizona, Colorado, New 
Mexico, Utah, and California provided information on stage at diagnosis, ER and PR tumor 
status, months of survival after diagnosis (calculated as difference between diagnosis date 
and date of death or last follow-up), and primary cause of death (International Classification 
of Diseases, 10th Revision) [44].
Statistical methods
The program STRUCTURE 2.0 was utilized to calculate individual proportion of genetic 
ancestry based on two founding populations (European and NA) [28, 45]. Participants were 
classified by level of percent NA ancestry, which was categorized based on the distribution 
of NA ancestry in the control population. Percent NA ancestry was evaluated by three 
groups (low <29 %, moderate 29 to ≤70 %, and high >70 %), to allow sufficient power to 
assess associations of ancestral groups with breast cancer risk and mortality as previously 
described [28]. Findings are presented by two NA ancestry groups (<29 %, ≥29 %) because 
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most of the estimates for breast cancer risk and mortality are not divergent for moderate or 
high NA ancestry groups; thus increasing power for this group.
Descriptive statistics were calculated for all covariates by level of percent NA ancestry and 
case–control status, and chi-square (χ2) tests were used to assess differences between 
groups. Minor allele frequencies (MAF) and Hardy–Weinberg equilibrium (HWE) p values 
were calculated based on the frequencies of alleles and genotypes in the control population. 
Unconditional multivariable logistic regression was used to estimate odds ratios (ORs) and 
95 % confidence intervals (CIs) for breast cancer risk associations with SNPs. SNPs were 
further evaluated for their association with breast cancer risk by strata of race/ethnicity, NA 
ancestry, menopausal status, HT use (never, ever, former, current), and OC use (never, ever) 
for all women. Risk of developing a particular breast cancer subtype based on ER/PR tumor 
phenotype) was evaluated using multinomial logistic regression [46, 47] for the 4-CBCS and 
SFBCS.
Initially, a co-dominant mode of inheritance was used to determine the relationship between 
number of alleles expressed and risk of breast cancer or breast cancer death. The assumed 
co-dominant mode of inheritance allowed us to evaluate whether there was a trend toward a 
dominant or recessive genetic model, and whether there was power to collapse genotype 
groups. SNPs were also assessed as continuous variables, and linear trend p values for the 
overall model (and within strata) were reported. All models were evaluated, and the most 
appropriate models for each SNP were selected for subsequent analyses. Confounding by 
categories of body mass index, first-degree family history of breast cancer, menopausal 
status, parity, OC use, HT use, alcohol consumption, and smoking status, continuous 
measures of physical activity and NA ancestry were evaluated. Covariates were considered 
confounders if the univariate p value was ≤0.20 and adjustment produced a change of ≥10 % 
in the effect estimate for the overall association of the genotype with breast cancer risk [48]. 
We did not observe confounding by any factor assessed. However, all models were adjusted 
for matching variables of age and study center as well as by NA ancestry. For stratified 
analyses, tests for interactions were calculated using a one degree of freedom (1 df) 
likelihood ratio test for logistic regression models with and without an interaction term. All 
cases (in situ and invasive) and controls were included in the analysis of breast cancer risk 
(n = 7,733). Sensitivity analysis restricted to only invasive cancers was not conducted 
because it would limit power as well as comparisons to the estimates including all women, 
because stage of disease is not available for MBCS participants.
For survival analyses, associations between SNPs and breast cancer mortality were 
evaluated using multivariable Cox proportional hazard models to obtain hazard ratios (HRs) 
and 95 % CIs adjusted for SEER summary stage at diagnosis (local, regional, and distant), 
age, NA ancestry, and study center. Participants were censored if lost to follow-up or died of 
cause other than breast cancer. Stratified analyses were conducted to determine the presence 
of effect modification by race/ethnicity, NA ancestry, and menopausal status and assessed 
using p values from 1 df likelihood ratio tests. Invasive cases from 4-CBCS and SFBCS with 
available data for survival and stage were included in the survival analysis (n = 2,218).
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p values from linear trend tests and interactions in overall models and within stratum were 
adjusted for multiple comparisons (MCs) within each gene using a step-down Bonferroni 
correction method [49]. This method takes into account the correlation of the data using the 
SNP spectral decomposition method based on the eigenvalues of the correlation matrix 
among the SNPs for each gene as proposed by Nyholt [50] and modified by Li and Ji [51]. 
The effective number of independent SNPs is determined and used when adjusting for MC, 
rather than total SNP number. This method is conservative, especially when evaluating 
correlated variables such as SNPs within a gene. However, it is less conservative than the 
conventional Bonferroni correction because you have more opportunities to reject the null 
hypotheses, which results in an increase in statistical power [51]. An adjusted p ≤ 0.05 (α = 
0.05) for main effects and interactions was considered statistically significant. All statistical 
analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC).
Results
Breast cancer cases included in this study were predominantly postmenopausal (59.7 %) and 
between the ages of 40–59 years of age (58.7 %) (Table 1). Compared to women with low 
NA ancestry (<29 %), cases and controls, respectively, with moderate to high NA ancestry 
(≥29 %) had a higher proportion of premenopausal status (40.3 and 39.9 vs. 33.6 and 31.5 
%), a low proportion tended to report ever use of HT (27.5 and 25.6 vs. 53.4 and 54.0 %) 
and OC (54.1 and 52.8 vs. 69.6 and 64.9 %), and cases more frequently presented with ER
−/PR− tumors (17.4 vs. 13.2 %) and regional stage of disease (38.9 vs. 29.8 %). Majority of 
cases and controls with low NA ancestry were NHW ethnicity (83.7 and 85.0 %, 
respectively), whereas cases and controls with moderate to high NA ancestry were 
predominantly Hispanic/NA ethnicity (99.4 and 99.7 %, respectively). A similar proportion 
of breast cancer cases were deceased in low NA ancestry (15.8 %) and moderate to high NA 
ancestry (16.3 %), and majority of deaths were due to breast cancer (56.6 and 62 %, 
respectively) (data not shown in table). Table 2 provides a description of the selected SNPs. 
CYP19A1 (rs700518) is located in exon 3; both rs4646 and rs4275794 are located in the 3′-
untranslated region (c).
Associations with breast cancer risk
When considering all women combined, we did not observe any significant associations 
between the 25 tag-SNPs on CYP19A1 and breast cancer risk after MC adjustment. Prior to 
MC adjustment, one SNP (rs4646) was inversely associated with breast cancer risk for all 
women (ORAA 0.87, 95 % CI 0.77–0.98) (Table 3). Results stratified by NA ancestry were 
divergent between women with low (<29 %) or moderate to high (≥29 %) NA ancestry for 
several SNPs. We observed inverse associations (OR 0.64–0.82) for the variant alleles in 
three SNPs (rs10459592, rs1961177, and rs6493497) and positive associations (OR 1.20–
1.67) for variant alleles in five SNPs (rs4275794, rs2899472, rs700518, rs12908960, and 
rs11856927) for women with ≥29 % NA ancestry, compared to women with <29 % NA 
ancestry (Table 3). After MC adjustment, two SNPs remained significantly associated with 
increased breast cancer risk in women with ≥29 % NA ancestry (rs700518, ORGG 1.36, 95 
% CI 1.11–1.67) and (rs11856927, ORTG 1.20, 95 % CI 1.05–1.36) and (ORGG 1.35, 95 % 
CI 1.05–1.72). We observed several interactions with NA ancestry; however, none of these 
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associations remained statistically significant after MC adjustment (Table 3). Results were 
similar when stratified by race/ethnicity for all women (NHW vs. Hispanic/NA) as well as 
by NA ancestry within Hispanic/NA only (data not shown). There was one significant 
interaction observed with menopausal status after MC adjustment: rs2470144 (padj = 0.03); 
breast cancer risk was increased among postmenopausal women (ORAA 1.22, 95 % CI 1.05–
1.14); however, an inverse relationship was seen among premenopausal women (ORAA 
0.78, 95 % CI 0.64–0.95) (data not shown in table).
CYP19A1 gene–environment interactions and breast cancer risk
We considered possible interactions between CYP19A1 SNPs and HT use and OC use. None 
of the observed interactions remained statistically significant after MC adjustment (data not 
shown). None of the SNPs were considered significantly associated with breast cancer risk 
when considering breast cancer subtypes defined by ER/PR tumor phenotypes.
Associations with breast cancer mortality
None of the CYP19A1 SNPs were associated with risk of breast cancer mortality, for all 
cases combined after MC adjustment. Only rs2470152 was associated with an increased risk 
(HRCC = 1.40, 95 % CI 1.03–1.91, padj = 0.48) prior to MC adjustment (Table 4). Prior to 
MC adjustment, we observed an interaction between rs12591359 and NA ancestry (p = 
0.03): a modest increase in risk for those with <29 % NA ancestry (HRAA = 1.70, 95 % CI 
1.00–2.62) and a non-significant reduced risk for those with ≥29 % NA ancestry (HRAA = 
0.77, 95 % CI 0.45–1.34). Additionally, three SNPs (rs2414099, rs2445762, and rs8025191) 
showed inverse associations for the variant allele(s) within the <29 % NA ancestry strata 
(HR = 0.59–0.65) (Table 4). However, tests of interaction were not statistically significant 
for any of these SNPs after MC adjustment. Analyses stratifying by menopausal status 
showed no statistical significant associations after MC adjustment.
Discussion
We examined the associations between 25 tagSNPs in CYP19A1, a gene involved in the 
biosynthesis of estrogen, and breast cancer risk and mortality among Hispanic/NA and 
NHW women taking into account the proportion of NA ancestry. We also evaluated 
associations taking into account breast cancer subtypes defined by ER/PR status, 
menopausal status, and possible gene by environment interactions considering HT and OC 
use. None of the SNPs remained significantly associated with breast cancer risk after MC 
adjustment. However, many associations tended to differ by NA ancestry groups and two 
SNPs (rs700518 and rs11856927) remained associated with a slightly increased risk of 
breast cancer among women with moderate to high NA ancestry; these associations 
withstood MC adjustments. There was one significant interaction with menopausal status 
(rs2470144) in which risk was increased for postmenopausal women only. Generally, there 
were no distinct associations when considering breast cancer subtypes defined by ER/PR, or 
interactions with HT or OC use. None of the SNPs remained significantly associated with 
breast cancer mortality overall or when stratified by NA ancestry after MC adjustment.
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The CYP19A1 gene encodes for aromatase, a 503-amino acid protein containing nine coding 
exons, is found to be expressed in breast tissue, and is also the source of local estrogen 
production in breast tumors [52]. The expression of CYP19A1 is regulated by tissue-specific 
promoters which differ between normal breast tissue and breast cancer tissue. The switch in 
promoters alters plasma estrogen levels that influence estrogen levels in normal breast tissue 
and breast cancer tissue and are related to increased risk of breast cancer [7, 10]. Due to the 
fact that the majority of breast cancers are hormone receptor positive and driven by the ER 
signaling pathway, genetic variation of genes involved in regulation of hormone production 
is hypothesized to be a plausible factor in breast cancer susceptibility and survival.
Generally, epidemiology studies including predominantly NHW populations have found that 
genetic variants in CYP19A1 do not have a strong effect on breast cancer risk, regardless of 
study design (case–control vs. cohort, tagSNP vs. haplotype approach) [10, 11, 13, 15, 17–
20, 53–59]. Some studies found associations among subgroups, for example: NHW 
premenopausal women and ER− tumor status [53], and Japanese women with ER+ 
premenopausal breast cancer [59]. One study found a significant increase in endogenous 
estrogen levels associated with several SNPs in NHW postmenopausal women [13]. 
Diergaarde et al. [60] evaluated an interaction between several CYP19A1 polymorphisms 
and HT use and did not find any significant associations in a NHW population, similar to 
our findings in this genetically admixed population. Furthermore, several studies [21–26] 
have examined genetic variation on CYP19A1 and risk of breast cancer mortality, although 
findings are mixed. For example, Long et al. [22] found an increased risk of breast cancer 
mortality for five CYP19A1 SNPs in a Chinese population, while Fasching et al. [21] found 
an inverse relationship for one SNP (rs10046) and Udler et al. [23] did not find associations 
with four CYP19A1 SNPs in a NHW population. This study does not provide conclusive 
evidence that genetic variation in CYP19A1 is a prognostic factor for breast cancer 
mortality, or that NA ancestry modifies the association.
To our knowledge, the three tagSNPs we found associated with breast cancer risk in 
moderate to high NA ancestry (rs700518 and rs11856927) and postmenopausal women 
(rs2470144) have not been previously evaluated in epidemiology studies. We utilized the 
program SNAP (SNP Annotation and Proxy Search, Broad Institute) [61] to evaluate 
whether these three SNPs were in high LD with SNPs reported in previous literature. Pair-
wise LD is pre-calculated based on phased genotype data from the International HapMap 
Project [62]. CYP19A1 rs11856927 or rs2470144 was not found to be in high LD with 
previously reported SNPs. CYP19A1 rs700518 and rs10046 are in high LD (r2 = 0.87) in the 
CEU population (European ancestry); however, we do not know if it is in high LD in the 
Mexican ancestry population (MEX). CYP19A1 rs700518 and rs4775936 are also found to 
be in high LD in both CEU and MEX populations (r2 = 0.81 and r2 = 0.87, respectively). 
CYP19A1 rs10046 (T) and the rs4775936 (A) are reportedly associated with higher levels of 
circulating estrogen or estrogen to androgen ratios in several studies [10–13, 15]. Despite 
this relationship, studies have not consistently found an association between these two SNPS 
and breast cancer risk [15, 63]. One study found that rs10046 is associated with breast 
cancer risk in Chinese women [64]. In addition to being in LD with these two SNPs that 
influence estrogen levels, CYP19A1 rs700518 is located in a coding region (exon 3) and was 
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found to be an ‘allelic expression marker’; part of a haplotype that is associated with 
expression of this aromatase gene [14]. Moreover, CYP19A1 rs700518 has been reported as 
a predictor of endocrine therapy effectiveness in ER+ breast cancer [65].
Findings from our study indicate that NA ancestry may modify the association between 
genetic variation in CYP19A1 and breast cancer risk. Two possible explanations for the 
observed results include: (1) Selected genetic variants in CYP19A1 may be susceptibility 
loci or surrogates for unmeasured functional variants that are more frequent in women with 
higher NA ancestry and influence differences in breast cancer risk; and (2) estimated NA 
ancestry may serve as a genetic component to the difference in breast cancer risk. 
Additionally, we cannot rule out the possibility of three-way gene–environment interactions 
with CYP19A1 variants, NA ancestry, and environmental factors, which future research 
could explain. Further evaluation of genetic variants associated with breast cancer risk that 
varies in frequency and LD patterns across racial/ethnic groups is needed and may help to 
identify regions of the genome associated with breast cancer by ethnic groups [36]. For 
example, Fejerman et al. used an admixture mapping approach and confirmed that the 
observed association between genetic ancestry and breast cancer risk and is in part due to 
admixture signals in genomic regions (6q25 and 11p15) that differ between indigenous 
European and NA ancestral groups [30].
This study has several strengths and limitations. This is the first study to evaluate genetic 
variation on the CYP19A1 gene in Hispanic/NA women and NA ancestry groups. The large 
sample size allowed us to evaluate different modes of inheritance and to conduct stratified 
analyses. Nevertheless, power was limited when assessing breast cancer survival and ER/PR 
status, partly due to lack of data from the MBCS. A strength of the survival analyses 
conducted is the long follow-up period for 4-CBCS and SFBCS, approximately 8 and 10 
years, respectively. When stratifying by NA ancestry, we reported estimates including both 
Hispanic/NA and NHW in the analyses of breast cancer risk and mortality. We were able to 
rely on genetic markers to determine ancestry and not assume ancestry based on self-
reported race. Moreover, women from Mexico were not asked their race/ethnicity and were 
all considered Hispanic. Interestingly, that study population includes a small proportion of 
women with low NA ancestry. Some Hispanics/NA in 4-CBCS and SFBCS also have low 
NA ancestry. Additionally, utilizing a tagSNP approach we were able to cover variation 
across the entire gene; however, this approach resulted in assessment of many SNPs making 
it difficult to observe significant findings after adjustment for MC, which was conservative 
and may result in false-negative associations. Lastly, after FDR adjustment, one SNP 
(rs4646) was found to violate HWE and was kept in analysis because these results indicate 
that there is a difference in observed genotypes by ethnic groups, which we hypothesize, 
may be due to biological differences in ancestry and may be informative for future studies 
including women of NA ancestry.
In conclusion, our unique findings suggest there is a positive association with genetic 
variants in CYP19A1 and breast cancer risk in women of moderate to high NA ancestry, 
which was not observed in women with low NA ancestry. The plausible functionality of 
CYP19A1 rs700518 could justify the association observed in women with moderate to high 
NA ancestry; however, this finding needs to be replicated. These results strengthen the 
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hypothesis that the proportion of estimated NA ancestry may influence biological pathways, 
increasing susceptibility to breast cancer.
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Table 1
Descriptive characteristics by Native American ancestry and case–control status: the Breast Cancer Health 
Disparities Study (n = 7,733)
Characteristic <29 % Native American ancestrya ≥29 % Native American ancestryb
Cases n (%) Controls n (%) Cases n (%) Controls n (%)
Total subjectsc 1,696 (21.9) 1,871 (24.2) 1,828 (23.6) 2,338 (30.2)
Study site
 4-CBCS 1,267 (74.7) 1,462 (78.1) 489 (26.8) 609 (26.1)
 MBCS 26 (1.5) 11 (0.6) 790 (43.2) 983 (42.0)
 SFBCS 403 (23.8) 398 (21.3) 549 (30.0) 746 (31.9)
Race/ethnicity
 Non-Hispanic White 1,420 (83.7) 1,591 (85.0) 11 (0.6) 8 (0.3)
 Hispanic 276 (16.3) 280 (15.0) 1,817 (99.4) 2,330 (99.7)
Age (years)
 <40 109 (6.4) 149 (8.0) 176 (9.6) 281 (12.0)
 40–49 483 (28.5) 485 (25.9) 626 (34.3) 758 (32.4)
 50–59 482 (28.4) 493 (26.4) 535 (29.3) 675 (28.9)
 60–69 398 (23.5) 405 (21.7) 367 (20.1) 481 (20.6)
 ≥70 224 (13.2) 339 (18.1) 124 (6.8) 143 (6.1)
Menopausal status
 Premenopausal 570 (33.6) 589 (31.5) 736 (40.3) 932 (39.9)
 Postmenopausal 1,070 (63.1) 1,236 (66.1) 1,035 (56.6) 1,338 (57.2)
 Missing 56 (3.3) 46 (2.5) 57 (3.1) 68 (2.9)
Hormone therapy use
 Never 481 (28.4) 529 (28.3) 1,155 (63.2) 1,580 (67.6)
 Ever 906 (53.4) 1,010 (54.0) 503 (27.5) 598 (25.6)
 Missing 309 (18.2) 332 (17.7) 170 (9.3) 160 (6.8)
Oral contraceptive use
 Never 484 (28.5) 629 (33.6) 813 (44.5) 1,077 (46.1)
 Ever 1181 (69.6) 1,214 (64.9) 989 (54.1) 1,234 (52.8)
 Missing 31 (1.8) 28 (1.5) 26 (1.4) 27 (1.2)
Estrogen/progesterone receptor statusd
 ER+/PR+ 786 (47.1) – 482 (46.4) –
 ER+/PR− 138 (8.3) – 92 (8.9) –
 ER−/PR+ 19 (1.1) – 24 (2.3) –
 ER−/PR− 221 (13.2) – 181 (17.4) –
 Missing 506 (30.3) – 259 (24.9) –
SEER summary staged
 Local 928 (69.1) – 526 (60.2) –
 Regional 401 (29.8) – 340 (38.9) –
 Distant 15 (1.1) – 8 (0.9) –
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4-CBCS 4-Corners Breast Cancer Study, MBCS Mexico Breast Cancer Study, SFBCS San Francisco Bay Area Breast Cancer Study. Column 
percentages may not add up to 100 % due to rounding
a
Statistically significant differences (p ≤ 0.05) between cases and controls in women with <29 % Native American ancestry for study and oral 
contraceptive use
b
Statistically significant differences (p ≤ 0.05) between cases and controls in women with ≥29 % Native American ancestry for hormone therapy 
use
c
Statistically significant differences (p ≤ 0.05) between Native American ancestry groups, regardless of case–control status, were observed for all 
variables
d
Data on ER/PR status and stage are for primary invasive cancers only and are not available for the Mexico site
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